5 Things You Need to Know in Cervical Cancer: New and Emerging Agents

5 Things You Need to Know in Cervical Cancer: New and Emerging Agents is organized by ReachMD.

Release Date: 09/29/2022
Expiration Date: 09/29/2023

Overview:
The global burden of cervical cancer is immense, especially for patients who have failed first-line therapy. Second-line interventions have historically had low response rates of short duration. But the landscape is changing with new and emerging agents in late-stage clinical trials, including antibody-drug conjugates, immunotherapy regimens, and tumor-infiltrating lymphocyte therapies. Join Drs. Robert Coleman and Kathleen Moore as they discuss and distill the “need to know” findings about these more effective therapies—therapies destined to improve outcomes for patients whose cervical cancer has failed first-line therapy.

Learning Objectives:
After participating in this educational activity, participants should be better able to:
• Identify the mechanism of action, efficacy, and safety data for new and/or emerging treatments for cervical cancer.
• Describe the benefits offered by participation in clinical trials for appropriate patients with cervical cancer.